Open access peer-reviewed chapter

2-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier

By Stevan P. Tofovic and Edwin K. Jackson

Submitted: February 8th 2019Reviewed: May 13th 2019Published: July 9th 2019

DOI: 10.5772/intechopen.86812

Downloaded: 177


Pulmonary arterial hypertension (PAH), a debilitating and incurable disease, predominantly develops in women. Estradiol metabolism leads to the production of numerous metabolites with different levels of estrogenic activity and very often opposing biological effects. Dysregulated estradiol metabolism was recently linked to the penetrance, progression, and prognosis of the disease. Ongoing clinical trials are examining the effects of estradiol synthesis/signaling inhibition in patients with PAH. In this chapter, the effects of sex, sex hormones, and estradiol metabolism on the healthy pulmonary circulation and vascular pathobiology are discussed in the light of estradiol metabolism as potential pharmacological target in PAH. The effects of estrogens and their metabolites on vascular pathobiology and disease progression, their involvement in PAH-associated diseases, and the pros and cons for interventions at different levels of estradiol metabolism are discussed. Finally, we propose that 2-methoxyestradiol (2ME), a major non-estrogenic metabolite of estradiol, mediates at least in part the beneficial effects of estradiol and that 2ME exhibits opposing effects to estradiol on several processes relevant to the underlying pathophysiology of PAH, including angiogenesis, metabolic reprograming, inflammation, and immunity. Based on cellular and in vivo effects, 2ME should be viewed as a disease modifier in women with PAH.


  • pulmonary hypertension
  • estradiol metabolism
  • 2-methoxyestradiol
  • angiogenesis
  • inflammation

1. Introduction

Pulmonary arterial hypertension (PAH) is a progressive incurable disease of pulmonary vasculature that ultimately leads to failure of the right ventricle (RV) and death. Notably the disease predominantly develops in women. The first report in 1951 by Dr. David Dresdale and colleagues from Maimonides Hospital of Brooklyn on hemodynamic aspects of primary pulmonary hypertension (PH) included three 25- to 35-year-old women [1]. Similarly, in 1952 in the second seminal report on PAH, British cardiologist Paul Wood recognized that this is “…relatively rare disease, usually encountered in women between 20 and 30, but may be met at any age and in either sex…” [2]. These early observations of female preponderance of PAH were confirmed by epidemiological studies conducted in the last two decades, and the data from various registries worldwide report a female-to-male ratio (F:M) ranging from 2:1 to 4:1 [3, 4, 5, 6, 7, 8, 9] and up to 4:1 to 9:1 for connective tissue disease [10, 11, 12]. However, with aging the female preponderance of disease disappears, and an M:F of only 1.2:1.0 has been reported in elderly PAH patients [13]. The latter strongly suggests involvement of female sex hormones in the development of PAH.

1.1 Vascular pathobiology in PAH

Pulmonary vascular remodeling is a pathological hallmark of PAH. Vascular morphological manifestations of the disease include (i) concentric and asymmetric obliterative proliferation of endothelial cells (ECs) and distal formation of multicellular plexiform lesions (PLXL); (ii) the muscularization of distal non-musculinized precapillary vessels; (iii) adventitia remodeling in form of fibrosis, inflammation, and perivascular edema; and (iv) PLXL, dilation lesions, and arteritis classified as complex lesions [14]. Three-dimensional analysis of vascular lesions in patients with severe PAH reveals the existence of two major phenotypes of ECs. The normal quiescent apoptosis-sensitive ECs are located in the peripheral areas of the lesion, are negative for phosphorylated MAPK, and have a high expression of p27kip1 (a marker of slow proliferation). The highly proliferative apoptosis-resistant cells in the central core of the vascular lesion have elevated MAPK activity and increased expression of HIF-1α, VEGF protein, and VEGF-2 receptor and low expression of p27kip1 [15, 16].

Both inflammation and immune cell response are recognized as important pathogenic factors in PAH [17, 18, 19]. For example, in experimental PH perivascular inflammation, due to macrophages, mast cells, and T and B lymphocytes, precedes vascular remodeling and elevated pulmonary pressure [20], and in PAH patients, the degree of perivascular infiltration by immune cells correlates with vascular remodeling and pulmonary artery pressure [21]. As discussed below, inflammation may markedly influence estradiol metabolism, and vice versa, estrogens and their metabolites may instigate, perpetuate, or inhibit inflammation and modulate immune cell responses in PAH.

2. Opposing effects of estradiol and 2-methoxyestradiol on estrogen metabolism

Since our first report that 2ME, a major non-estrogenic metabolite of 17β-estradiol (E2), attenuates the development and progression of monocrotaline (MCT)-induced PH and that estrogens may be pathogenic in PAH [22], a growing body of evidence suggests the involvement of dysregulated estradiol metabolism and elevated estrogen levels in the development, progression, and prognosis of PAH.

2.1 Increased estradiol production in PAH

Formation and metabolism of estrogens are complex (Figure 1). The pivotal precursors for synthesis of both androgens and estrogens are dehydroepiandrosterone (DHEA) and its biologically inactive sulfate (DHEA-S). DHEA is produced in the adrenal gland of men and postmenopausal women and in the ovaries and placenta of premenopausal women. DHEA, the most abundant steroid in circulation, is also produced by peripheral conversion from circulating DHEA-S. DHEA is transported into cells by organic anion transporters (OATPs) that are expressed in various tissues including the endothelial and inflammatory cells and lungs [23, 24, 25]. The delicate balance between DHEA and DHEA-S is controlled by the relative activity of sulfotransferase (DHEA → DHEA-S) and sulfatase (DHEA-S → DHEA) [26]. Both DHEA and DHEA-S are protective in experimental models of pulmonary hypertension [27, 28, 29, 30, 31] including models of angioproliferative PH [32, 33]. Recently, lower DHEA-S and higher E2 levels have been linked to a greater risk of PAH and worse hemodynamics, functional status, and greater risk of death [34, 35]. Notably, DHEA improves PAH in patients with obstructive pulmonary disease [36], a finding supporting the potential therapeutic application of DHEA in PAH patients. DHEA is an over-the-counter supplement with no major side effects; however, its safety during chronic use in pharmacological doses is unknown. One potential adverse effect in this regard would be increased circulating/tissue E2 levels that may exacerbate endothelial remodeling and inflammation (infra vide).

Figure 1.

Dehydroepiandrosterone is the most abundant steroid in circulation that is also produced by peripheral conversion from its circulating inactive sulfated metabolite DHEA-S. The balance between inactive sulfated sex steroids and sex steroids and their biologically active metabolites and metabolic precursors is controlled by sulfatase (STS) and sulfotransferase (SULT). Aromatase is a key enzyme in estrogen production because this enzyme controls aromatization of androgenic precursors to estrogens and intracrine production of estrogens. 2-Hydroxylation/methylation pathway of estrogen metabolism produces non-estrogenic metabolites with opposite effects to maternal estrogens. Hydroxylation of estradiol (E2) at C4 and C16 position leads to production of highly estrogenic metabolites with proliferative, pro-inflammatory, and angiogenic properties.

Aromatase (encoded by the CYP19A1 gene) is the rate-limiting enzyme catalyzing the conversion of upstream androgenic precursors to estrogens (androstenedione → estrone and testosterone → E2; Figure 1). In premenopausal women, estrogens are produced predominantly in the ovarian granulosa cells and are released into the bloodstream where they act primarily in an endocrine fashion. In postmenopausal women and in men, estrogen synthesis takes place in extra-gonadal tissues (liver, heart, skin/fat tissue, and brain) where estrogens act mainly as paracrine or autocrine factors. Aromatase expression in these various sites is under the control of tissue-specific promoters regulated by different cohorts of transcription factors. Therefore, aromatase activity differs substantially in various tissues and organs in health and disease [37]. Notably, human endothelium expresses a complete aromatase-estrogen-E2 receptor system [38], and increased expression of aromatase has been reported in hPASMCs from female PAH patients and in the lungs of female rats and mice with angioproliferative PH [39]. Increased aromatase activity and plasma E2 levels seen in both men and women with advanced liver disease is associated with increased risk of portopulmonary PAH [40], and increased aromatization of androgens and elevated E2 levels have been reported in postmenopausal women and in men with PAH [34, 35]. Noteworthy, E2 stimulates aromatase activity and by increasing aromatization of androgen precursors may augment its own production as well as production of E1. Because of the importance of this enzyme in estrogen synthesis, blocking aromatase activity is an important pharmacological tool used for the treatment of estrogen-dependent diseases (breast cancer, endometriosis, and endometrial cancer). Anastrozole (a third-generation aromatase inhibitor) reduces E2 levels and attenuates PH in female mice exposed to hypoxia [39] and in Sugene 5416 + hypoxia rats with angioproliferative PH [39, 41]. Moreover, when combined with the selective estrogen receptor degrader fulvestrant, anastrozole reverses PH in BMPR2-mutant mice [42]. Likewise, in PAH patients treatment with anastrozole reduces elevated E2 levels by 40% and E1 levels by 70% and significantly increases functional capacity, i.e., 6-minute-walk distance [43]. Notably, E2 augments gonadal aromatase activity, and by increasing aromatization of androgens, E2 may augment its own production as well as that of other estrogens [44]. Inflammation and inflammatory cytokines upregulate aromatase activity, and TNFα is one of the most potent inducers of aromatase. In contrast to estrogens that do not have effect on TNFα induction of aromatase [45], 2ME inhibits both basal and TNFα-stimulated aromatase activity [45, 46, 47].

In addition to aromatase, another potential source of increased estrogen production in PAH is the “sulfatase pathway.” In addition to DHEA-S, other substrates for STS are biologically inactive estrone sulfate (E1-S) and estradiol sulfate (E2-S), and sulfatase plays a key role in intracrine regeneration of biologically active E2 and E1 (Figure 1). Inflammatory cytokines increase STS activity. More importantly, STS expression is stimulated by estrogens via estrogen receptor alpha (ERα) signaling, and at least in breast cancer, STS is upregulated by the elevated local E2 levels [26]. Thereby, in an inflammatory environment, E2 through feed-forward mechanisms may increase its on production via both the sulfatase and aromatase pathways (Figure 2), as implicated by elevated aromatase activity and E2 levels in both experimental PH [39] and in men and women with PAH [34, 35, 40].

Figure 2.

Opposing effects of E2 and 2ME on estrogens and arachidonic acid metabolism. Inflammation and dual metabolic activity of CYP1B1 instigate estradiol feed-forward mechanisms that involve sulfatase, aromatase, COMT, and CYP1B1 (red arrows). Thereby, the increased E2 and arachidonic acid pro-inflammatory metabolites may contribute to the development of inflammatory and angioproliferative phenotypes in women. In contrast, 2ME by inhibiting CYP1B1 activity, macrophage influx/activation, and pro-inflammatory cytokine induction of estrogen-producing enzymes (blue arrows) balances inflammation and E2 production and its metabolisms into mitogenic pro-inflammatory and angiogenic metabolites. CYP1B1 activation results in production of pro-inflammatory arachidonic acid metabolites (black arrows). COMT = catechol-O-methyltransferase; CYP = cytochrome p450 enzymes; EETs = epoxyeicosatrienoic acids; HETEs = hydroxyeicosatetraenoic acids; sEH = soluble epoxide hydrolase, degrades EETs.

2.2 Dysregulated estradiol metabolism in PAH

Once formed, E2 is primarily metabolized by oxidation at C2, C4, and C16 positions and converted to metabolites with different estrogenic activities and diverse (often opposite) biological effects. In humans, E2 hydroxylation is mediated by multiplying CYP450 enzymes (CYP1A1/1A2/3A4/1B1) with 2-hydroxyestradiol (2HE) being the main metabolite; however, 4-hydroxyestradiol (4HE; Figures 1 and 2) is formed to a lesser degree (~5%). This is followed by methylation of hydroxyl groups catalyzed by catechol-O-methyl transferase (COMT). The hydroxylation/methylation pathway is a major metabolic pathway that accounts for ~50% of E2 metabolism. It largely takes place in the liver and leads to production of 2ME, a major non-estrogenic metabolite with antiproliferative, anti-angiogenic, and anti-inflammatory effects [48]. In addition to hepatocytes and numerous cancer cell lines, conversion of E2 to downstream 2HE and 2ME takes place in cardiovascular and renal compartments [48], and a solid line of evidence suggests that 2ME mediates the antiproliferative effects of E2 in cardiovascular and renal cells [49].

Notably, the protective effects of E2 in experimental PH are mediated, at least in part, by 2ME [50, 51]. Furthermore, it seems that in highly proliferative states, 2ME may oppose estrogen-driven proliferation. For example, in highly proliferative human leiomyoma cells (hLCs) characterized by doubled ERα signaling (inherently regulated by microtubule dynamics) [52], COMT overexpression or treatment with 2ME stabilizes microtubules, attenuates E2-induced proliferation, inhibits ERα signaling, and reduces HIF-1α and aromatase expression in hLCs [53, 54]. Unfortunately, it seems that elevated E2 levels seen in PAH may adversely affect both hepatic and extrahepatic 2ME production. In this regard, men have higher COMT activity than women [55, 56], and sex hormones regulate COMT activity that is highly expressed in human and rat lungs [57, 58]. The exposure to E2 reduces hepatic COMT activity in rats [59, 60]; in vitro E2 decreases COMT transcription, activity, and protein levels [61, 62]; and tamoxifen, by antagonizing E2, increases COMT activity in peripheral tissues [63]. Together, these findings suggest that reduced COMT activity by elevated E2 and subsequent decreased in 2ME production may render women more susceptible to the development of PAH. At present it is unknown whether there is reduced 2ME production in PAH. Yet, reduced 2ME production has been linked to the development of preeclampsia [64], increased sensitivity to angiotensin II [65], and insulin resistance [66].

2.3 Opposing effects of estradiol and 2-methoxyestradiol on CYP1B1 activity and estrogen and arachidonic acid metabolism

E2 and 2ME have opposing effects on CYP1B1, another E2 metabolizing enzyme implicated in pathogenesis of PAH. Human CYP1B1 mRNA and protein are constitutively expressed in the lung and in VSMCs and ECs [67]. CYP1B1 may facilitate E2 oxidation at C4 and C16, thus producing highly estrogenic and reactive metabolites 4-hydroxyestradiol (4HE) and 16α-hydroxyestrone (16αHE1). Experimental and human data suggest a major pathogenic role for CYP1B1 and 16αHE1 in PAH. In this regard, CYP1B1 increases the risk of PAH and RV dysfunction in humans and plays a pathogenic role in the 16αHE1-BMPR2 interaction in experimental PH [68, 69, 70, 71, 72, 73, 74, 75, 76]. Notably, E2 and 2ME have divergent effects on CYP1B1 activity. Estradiol is not only a substrate for CYP1B1, but also it is transcriptional activator of CYP1B1 [77]. In contrast, in vitro 2ME exerts feedback inhibition on CYP1B1 activity [78]. Moreover, 2ME inhibits aryl hydrocarbon receptor-mediated induction of CYP1B1 and reduces CYP1B1 production of reactive metabolites. In vivo, 2ME significantly inhibits CYP1B1 expression and attenuates pressure overload-induced cardiac remodeling [78, 79]. In vivo CYP1B1 inhibition by 2ME reduces biosynthesis of mid-chain hydroxyeicosatetraenoic acids (HETEs) [79], suggesting a significant role for CYP1B1 in arachidonic acid metabolism. Indeed, due to its lipoxygenase-like activity, CYP1B1 facilitates arachidonic acid metabolism into HETEs and epoxyeicosatrienoic acids (EETs) [80]. In the pulmonary vasculature, EETs and HETEs have vasoconstrictive, inflammatory, and mitogenic/angiogenic effects and have been implicated in the development of experimental hypoxic PH [81, 82, 83, 84]. Noteworthy, in PAH patients increased production of HETEs correlates with a poor prognosis [85]. E2 not only stimulates production of HETEs and EETs but also by inhibiting expression/activity of soluble epoxide hydrolase (sEH) [86] suppresses the degradation of EETs. Several lines of evidence link low sEH activity to the pathophysiology of PH: (1) the lungs from PH patients express no/little sEH; (2) E2-, genetic-, and pharmacologically induced downregulation of sEH potentiates hypoxic vasoconstriction; (3) hypoxia downregulates sEH; and (3) sEH−/− mice have exacerbated pulmonary vascular remodeling when exposed to chronic hypoxia [87, 88, 89]. Therefore, elevated E2 levels in PAH through a feed-forward mechanism may shift both E2 and AA metabolism toward production of pro-inflammatory/angiogenic/mitogenic metabolites. Based on its inhibitory effects, 2ME should suppress the production of these pathogenic E2 and AA metabolites (Figure 2).

3. Divergent effects of 2ME and estradiol in pulmonary endothelium in PAH

Dysregulated angiogenesis with formation of occlusive and plexiform lesions is a hallmark of PAH. Although estrogens provide protection in healthy systemic vascular beds, they have opposite effects on malignant proangiogenic/highly proliferative vessels [90] that share many similarities with vascular changes in PAH. The highly proliferative apoptosis-resistant cells in the central core of vascular lesions in PAH have elevated MAPK activity; increased expression of HIF-1α, VEGF protein, and VEGF-2 receptor; and low expression of p27kip1 (marker of low cell growth) [15, 16]. In human pulmonary artery ECs (hPAECs) and at physiological concentrations (1–10 nM), E2 (1) stimulates cell proliferation [91]; (2) promotes the phosphorylation of p42/44 and p38 MAPK via ERs; (3) downregulates the cell cycle inhibitor p27Kip1; (4) stimulates cell migration; (5) induces HIF-1α expression and VEGF synthesis; and (6) protects against apoptosis [92, 93, 94]. Also, E2 stimulates proliferation of human pulmonary artery vascular smooth muscle cells (hPASMCs). In canine pulmonary arterial segments, E2 tends to inhibit proliferation of PASMCs in segments with intact endothelium but significantly enhances proliferation in segments stripped of endothelium [95], suggesting opposite effects of E2 in intact versus injured pulmonary vessels. Thereby, in the pulmonary vasculature exposed to known and unknown multiple hits, estrogens may potentiate pathological endothelial remodeling in PAH (Figure 3).

Figure 3.

In the injured highly proliferative/angiogenic endothelium in pulmonary vasculature in PAH, 2ME behaves as biological antagonist of estradiol (E2). 2ME and E2 have opposite effects on key regulators of angioproliferation (p27Kip1, AKT, HIF1-α, VEGF), and 2ME is a more potent modulator of prostacyclin, endothelin, and nitric oxide synthesis/release than E2.

In contrast to E2, it is well established that 2ME has strong anti-angiogenic, antiproliferative, and pro-apoptotic effects [96] and thereby may prevent PAH or inhibit the progression of PAH. In this regard, of particular importance for PAH are the effects of 2ME on the HIF-1α/VEGF axis. One of the most consistently reported effects of 2ME is HIF-1α downregulation, and 2ME has been increasingly used as pharmacological tool to inhibit HIF-1α in numerous studies outside the PAH field. HIF-1α transcriptional activity regulates more than 40 genes and respective proteins, including those that play a key role in vascular reactivity and angiogenesis [97, 98]. The role of HIF-1α in PAH is supported by multiple findings including the following: (1) obliterative endothelial lesions in severe PH in humans overexpress HIF-1α [15]; (2) in experimental PH there is similar increase in HIF-1α that correlates with the development of PH and pulmonary vascular remodeling and RV hypertrophy; (3) heterozygous deficiency in HIF-1α protects against the development of PH [99, 100]; and (4) pathologic normoxic HIF-1α signaling activation leads to the glycolytic shift (the Warburg effect) in highly proliferative ECs [101].

Hypoxia stimulates 2ME formation which inhibits the production of hypoxia-driven angiogenesis and angiogenic cytokines (VEGF and FGF-2) [31, 102]. Therefore, 2ME should be viewed as a local modulator that fine-tunes the rate of angiogenesis. Recent studies in experimental PH support the notion of 2ME as a local anti-angiogenic factor in PAH and E2 as promoter of angiogenesis. For example, (1) basal HIF-1α protein expression is higher in female hPASMCs than in males; (2) the antimitogenic effects of 2ME in hPASMCs are associated with reduced HIF-1α expression; (3) 2ME attenuates intermittent and chronic hypoxia-induced PH [22, 103, 104]; (4) in both male and female hypoxic PH rats, 2ME attenuates the disease while decreasing HIF-1α protein expression [103]; (5) female rats with Sugene 5416 + hypoxia (SU+Hx)-induced PH have more severe occlusive and plexiform lesions and sporadically develop grade 6 lesions (necrotizing arteritis); (6) E2 exacerbates angioproliferative lesions and perivascular inflammation in ovariectomized SU+Hx rats [105, 106]; and (7) in intact female SU+Hx rats, 2ME, but not E2, exhibits therapeutic effects [107]. The effects of 2ME in PAH patients are unknown. Yet, at least in experimental angioproliferative PH, 2ME could be viewed as biological antagonist of E2 in the endothelium and as a modifier of “dysregulated angiogenesis.”

4. Metabolic reprograming and 2ME in PAH

The major metabolic changes that take place in PAH occur in the form of the shift from oxidative phosphorylation to glycolysis. Known as the Warburg effect, this event is frequently observed and has been systematically investigated in cancer tissue. Notably, the Warburg effect has also been reported in pulmonary vasculature cells in PAH patients [108] and linked to highly proliferative, angiogenic, and apoptosis-resistant cancer cells and vascular cells in PAH. Not surprisingly, the Warburg effect has been explored as a potential anti-angiogenic target in cancer and more recently in PAH. The HIF-1α transcription factor has been identified as a master hypoxic regulator responsible for the metabolic shift in PAH [101, 109]. Hypoxic induction of HIF-1α leads to overexpression of pyruvate dehydrogenase kinase (PDK) which results in inhibition of pyruvate dehydrogenase that shunts pyruvate into glycolysis and induces conversion of glucose to lactate [108]. Dichloroacetate (DCA), a PDK inhibitor, reverses the Warburg effect and exhibits therapeutic effects in several animal models of PH [110, 111, 112]. Because 2ME is a strong HIF-1α inhibitor, 2ME should induce metabolic reprograming in PAH. Presently, the effects of 2ME on metabolic reprograming in PAH are unknown. However, 2ME inhibits lactate-induced mitochondrial biogenesis in highly proliferative osteosarcoma cells, and in apoptosis-resistant melanoma cells, 2ME attenuates proliferation and glycolysis by inhibiting HIF-1α and PDK expression [113, 114, 115]. Therefore, 2ME could be viewed as modulator of metabolic reprograming. Further studies are warranted to investigate the effects of 2ME on the Warburg effect that in PAH is associated with highly proliferative, angiogenic, and apoptosis-resistant phenotypes (Figure 4).

Figure 4.

Cellular effects of 2ME that contributes to the reduced E2 production, inflammation, angioproliferation, metabolic reprograming, and vascular and right ventricular remodeling in PAH.

5. Anti-inflammatory and immunomodulatory effects of 2ME

Inflammation and altered immunity, i.e., perivascular accumulation of inflammatory and immune cells in pulmonary circulation, have been increasingly recognized as pathogenic factors in PAH [17, 18, 19]. In this regard, at young age women have more robust immune responses than men. Although initially beneficial, with aging these aggressive immune responses may become detrimental [116]. This may explain why various immune diseases are remarkably more frequent in women and why many immune diseases, such as systemic sclerosis (SSc), lupus, and mixed connective tissue disease, are associated with increased risk of PAH [117]. Furthermore, recently distinct immune phenotypes have been reported in PAH patients [118]. In experimental PH, dysregulated immunity in the form of deficient regulatory T-cell (Treg) activity contributes to increased inflammation [20]. Both alveolar macrophages and immune cells express steroidogenic enzymes including sulfatase and aromatase [119, 120, 121]. Inflammatory cytokines, prostanoids, and growth factors regulate the expression and activity of steroidogenic enzymes, and in turn, sex hormones may influence the production and release of these autocrine/paracrine mediators [122]. E2 upregulates CYP1B1, aromatase, and sulfatase activity and inhibits sEH activity. Therefore, in an inflammatory environment, E2 may boost its own production, and via a feed-forward mechanism, E2 may enhance the production of pro-inflammatory, angiogenic, and mitogenic estrogens and increase the accumulation of pro-inflammatory arachidonic acid metabolites (Figure 2). In contrast to E2, non-estrogenic 2ME exhibits significant anti-inflammatory effects, largely through suppression of tissue recruitment and activation of macrophages [123, 124]. This is one of the most consistent in vivo effects of 2ME seen in experimental models of cardiovascular and renal injury [125, 126] and in pulmonary hypertension [50, 51, 127, 128, 129]. 2ME, its metabolic precursor 2HE, and the synthetic analog 2-ethoxyestradiol inhibit influx and activation of macrophages in MCT- and bleomycin-induced PH, and this inhibition correlates with reduced PH, vascular remodeling, and fibrosis. 2ME and its metabolic precursor 2HE also inhibit the synthesis of leukotrienes [130]. Blocking of leukotriene production by macrophages prevents endothelial injury and reverses experimental PH [131]. In experimental autoimmune rheumatoid arthritis, 2ME slows down disease progression by inhibiting inflammatory cytokine mRNA (IL-1β, TNF-α, IL-6, and IL-17), leucocyte infiltration, and neovascularization [31]. In several models of autoimmune inflammatory disease, the beneficial effects of 2ME were ascribed to the inhibition of immune cell activation, proliferation, and pro-inflammatory cytokine release [31, 132, 133, 134]. Finally, in fibroblasts from SSc disease patients that are at high risk for developing PAH, 2ME reduces hypoxia-induced production of connective tissue growth factor and collagen I by inhibiting the PI3K/Akt/mTOR or HIFα signaling [135]. Collectively, these data in inflammatory and autoimmune diseases point toward 2ME as potential modulator of inflammation and immunity relevant to the development and progression of PAH.

6. 2-Methoxyestradiol and the renin-angiotensin system (RAS) in PAH

Evidence suggests that the renin-angiotensin system (RAS) contributes to the development of PAH [136, 137]. For example, (1) there is increased systemic RAS activity in patients with idiopathic PAH; (2) in experimental and human PH, ACE activity and expression are increased in PAECs, PVSMCs, plexiform lesions, and the RV; (3) increased Ang II type 1 receptor expression and signaling correlates with PAH progression and vascular remodeling [137, 138, 139, 140, 141, 142]; and (4) inhibition of RAS slows down the progression of MCT-induced PH [143]. Cumulating data also suggests that 2ME may behave as biological antagonist of Ang II. 2ME downregulates Ang II type I receptors [144, 145, 146]. In COMT−/− mice that have reduced 2ME production, 2ME treatment abolishes hypersensitivity to and injury induced by Ang II [65]. Furthermore, in Cyp1B1−/− mice that also have reduced 2ME production, 2ME treatment abolishes Ang II-induced oxidative and vascular injury [147]. Finally, of relevance in PAH, in vivo in high RAS activity models, 2ME attenuates Ang II-induced cardiac and vascular remodeling and fibrosis and isoproterenol-induced RV and LV hypertrophy and fibrosis [148].

7. Role of 2ME and the metabolic syndrome in PAH

The metabolic syndrome (MS) is recognized as risk factor for PH [149, 150]. Deficiency in PPARγ (a downstream target of BMPR2) and deficiency in apolipoprotein E and adiponectin (downstream targets of PPARγ) have been linked to the development of PH in rodents [151, 152, 153]. Moreover, COMT, via methoxyestradiols, has been identified as a major factor modulating insulin resistance. The low-activity COMT158Val-Met is linked to MS [154], whereas high-activity COMT rs4680 is associated with lower HbA1c levels and protection from type 2 diabetes [155]. COMT deficiency in mice leads to disrupted glucose homeostasis [66], and 2ME which shares structural similarity with PPARγ ligands and acts as a PPARγ agonist [65, 156] (Figure 4) induces AMPK phosphorylation and improves insulin sensitivity in COMT−/− mice [66]. 2HE, a metabolic precursor of 2ME and COMT substrate, activates AMPK in human skeletal muscle, attenuates experimental PH in lean rats, and reduces MS-induced endothelial dysfunction in obese rats. Moreover, in rats with polygenic obesity and MS, in both PH-free females and PH male ZDSD rats, treatment with 2HE reduces glycosylated hemoglobin, RVPSP, and RV-EDP and attenuates vascular remodeling in male PH rats [157]. These data warrant further investigation of 2ME in MS-induced PH and support the notion of 2ME as potential disease modifier in MS-related PH.

8. 2-Methoxyestradiol and current pharmacotherapy of PAH

Despite significant advances in pharmacotherapy of PAH, mortality of patients with PAH remains high. Therefore, there is still a significant unmet medical need for more effective therapies. Currently approved drugs for treatment of PAH include medications that correct for prostanoid deficiency (prostanoids and prostacyclin receptor agonists) and deficiency of nitric oxide (PDE5 inhibitors and soluble guanylate cyclase stimulators) or combat overproduction of endothelin (endothelin receptor antagonists). Compared to ECs in healthy vessels, the ECs in affected vessels in PH show reduced prostacyclin and nitric oxide synthesis and overexpression of ET-1 [158, 159, 160]. Noteworthy, compared to estradiol, 2ME is a more potent inhibitor of endothelin synthesis in endothelial cells [48, 161], and 2ME and its metabolic precursor 2HE inhibit endothelin-induced vasoconstriction [162]. Furthermore, in ECs 2ME is a more potent stimulator of prostacyclin synthesis than estradiol [163, 164]. 2ME also increases basal and potentiates stimulated NO production in male and OVX female rats, but has no effect in intact females, and in vitro these effects are abolished by the eNOS inhibitor L-NAME [165]. 2ME induces vasodilation by stimulating NO release via PPARγ/PI3K/Akt pathway [166] and increases NO production in uterine artery ECs from pregnant sheep [167]. Moreover, in L-NAME-treated rats, 2ME attenuates severe hypertension and renal, cardiac, and vascular injury and inflammation and reduces mortality by 87% [125]. Likewise, 2ME exhibits beneficial effects in MCT-induced PH and efficacy comparable to that of bosentan and sildenafil. Importantly, in combination with bosentan or sildenafil, 2ME has synergistic therapeutic effects (further reduces vascular remodeling, inflammatory responses, and survival) [128]. Finally, none of the approved therapies for PAH affects endothelial remodeling and “dysregulated angiogenesis” in pulmonary vasculature; in contrast, as discussed above in Section 3, 2ME is a strong anti-angiogenic agent and inhibitor of HIF-VEGF axis that is critical for the metabolic shift and development of occlusive and complex vascular lesions. Altogether, these data clearly indicate 2ME as a promising pharmacological agent capable of providing additional benefit in PAH patients on standard single or combination therapy.

9. Pharmacokinetic aspects of the development of 2ME as a disease modifier in PAH

The safety and efficacy of 2ME in human PAH are unknown. However, over the past two decades, numerous phase I and II clinical trials have been conducted to test the safety and antitumor efficacy of 2ME in patients with solid malignancies. These studies show that 2ME is well tolerated and safe in doses up to 3 g/day. Unfortunately, even high oral doses of 2ME achieve only low plasma 2ME concentrations due to high pre-systemic metabolism (glucuronidation) in the liver. In experimental PH, therapeutic effects of 2ME are achieved by much lower doses (240 μg/kg/day) delivered by subcutaneous micro-infusions that produce high physiological concentrations of 2ME (~3 ng/ml; equivalent to levels observed during the last trimester of pregnancy) [168]. At these concentrations, 2ME does not induce estrogenic effects. In rats with MCT-induced PH, although higher doses of 2ME do not additionally reduce PH and RV hypertrophy, higher doses do further inhibit media remodeling and inflammation [127]. Likewise, in contrast to oral administration in healthy volunteers and cancer patients, subcutaneous administration of a long-acting formulation of 2ME in doses up to 10 mg produced blood levels of 2ME >1 ng/ml over a 3-week period, with no estrogenic or other adverse effects reported [169]. Currently, various parenteral formulations of 2ME with supposedly high bioavailability are under investigation.

10. Conclusions and future directions

An expanding body of knowledge indicates that many of the beneficial cellular and systemic effects of E2 are due, at least in part, to its major and non-estrogenic metabolite 2ME. This underscores the importance of estradiol metabolism to 2ME in women’s health and suggests that 2ME deficiency may contribute to many female predominant diseases, including PAH. 2ME should not be viewed only as partial mediator of E2 effects but in PAH should be considered a moderator of the harmful effects of estrogens related to several key events in PAH including altered estradiol and arachidonic acid metabolism, angiogenesis, inflammation, harmful immune responses, metabolic syndrome, and metabolic reprograming. The above discussion hopefully makes the case for 2ME as unrecognized disease modifier in PAH.

Conflict of interest

The authors do not have any conflict of interest.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Stevan P. Tofovic and Edwin K. Jackson (July 9th 2019). 2-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier, Interventional Pulmonology and Pulmonary Hypertension - Updates on Specific Topics, Theodoros Aslanidis, IntechOpen, DOI: 10.5772/intechopen.86812. Available from:

chapter statistics

177total chapter downloads

1Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Introductory Chapter: Whole Lung Lavage for Pulmonary Alveolar Proteinosis—The Challenges Remain

By Theodoros Aslanidis

Related Book

First chapter

Introductory Chapter: Hemodynamic Management. The Problem of Monitoring Choice

By Theodoros Aslanidis

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us